William Looney
Editor-in-Chief
wlooney@advanstar.com
William Looney is the Editor in Chief of Pharmaceutical Executive magazine, a monthly print and weekly on-line publication focused on the “c suite” concerns of senior managers in the biopharmaceutical industry. In addition to editorial content, he is responsible for supporting the magazine through related educational media activities and serving as a thought leader in contacts between the magazine and a wide variety of organizations.
Prior to joining Pharmaceutical Executive in August 2009, Mr. Looney served for 11 years as Senior Director at Pfizer, Inc. where he managed the company’s public policy issue development, positioning and advocacy activities outside the US. In that capacity, he worked closely with the academic and think tank community, coordinated Pfizer CEO relationships with the World Economic Forum, Japan’s Nikkei Management Forum and other policy groups, and chaired committees of key biopharma trade associations, including PhRMA and the IFPMA.
Earlier in his career, he served as an internal communications manager and speech writer at Warner Lambert Company in both the US and in Europe. He also was senior editor for the Economist Intelligent Unit, where he was responsible for consumer issues and management practices in Europe.
He has also been a consultant to the organization for Economic Cooperation and Development [OECD], and is the author of numerous research papers and studies focused on the relationships between product and process innovation and public health.
In March 2011 he was honored by American Business Media with a Neal Award for 'Best Commentary' for his monthly 'From the Editor' columns.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.